Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Specialty Process Labs LLC
WARNING LETTER
•Specialty Process Labs LLC•November 19, 2021

Specialty Process Labs LLC – FDA Warning Letter, Nov 19, 2021

Record Details

The FDA inspected Specialty Process Labs LLC's drug manufacturing facility in Phoenix, Arizona, from November 8-19, 2021, identifying significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API), rendering their API adulterated.

Key violations include: 1. **Failure to validate manufacturing processes:** Specifically, the thyroid, USP API process validation was inadequate, omitting several processing steps and failing a performance qualification for blending. The company's response was insufficient, lacking detailed protocols, timelines for prospective process performance qualification (PPQ) studies, and an assessment of the impact on currently marketed API. 2. **Inadequate laboratory testing:** The firm failed to retest API lots held for extended periods before blending, and final API was labeled with a re-evaluation date based on blending, not the oldest lot's manufacturing date. The response lacked timelines for corrective actions and stability studies. 3. **Insufficient computerized system controls:** Many systems lacked controls to prevent unauthorized access or data omission. The company's retrospective review plan was inadequate, lacking timelines and interim measures. 4. **Deficient microbiological test methods:** Microbiological test methods for thyroid, USP API were deficient, and the response lacked timelines, interim measures, and commitment to growth promotion testing. 5. **Quality unit failures:** The quality unit failed to perform routine functions, including vendor oversight and batch review. The response lacked timelines for corrective actions

Company
Specialty Process Labs LLC
Inspection date
November 19, 2021
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
People
  • Steven E. Porter (Program Division Director)
  • Thomas K. Langdon
View Company Profile

ID · e2c96ccb-8f3a-4f59-9a86-7f1f4c55b44a

Violation Codes2
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Specialty Process Labs LLC
  • 483 - 2025-07-21July 21, 2025
  • 483 - 2024-01-26January 26, 2024
  • 483 - 2023-09-15September 15, 2023
  • 483 - 2021-11-19November 19, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Specialty Process Labs LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.